Skip to main content

Table 1 Demographic characteristics of participants

From: Clinical significance of focal ß-amyloid deposition measured by 18F-flutemetamol PET

 

No-FMM uptake (n = 174)

Focal-FMM uptake (n = 53)

Diffuse-FMM uptake (n = 83)

p

No vs focal uptake

p

No vs diffuse uptake

p

Focal vs diffuse uptake

Age (mean ± SD)

69.4 ± 8.6

73.5 ± 7.9

71.4 ± 8.5

0.008

0.253

0.494

Men (%)

73 (42.0)

15 (28.3)

37 (44.6)

0.075

0.692

0.058

Education, years (mean ± SD)

10.7 ± 5.0

10.3 ± 5.0

11.0 ± 4.5

1.000

1.000

1.000

APOE ε4 carrier (%)

21/166 (12.7)

23/53 (43.4)

42/81 (51.9)

< 0.001

< 0.001

0.340

Disease duration (months) (Mean ± SD)

62.5 ± 52.9

50.3 ± 44.5

41.5 ± 41.6

0.455

0.009

1.000

Vascular risk factors

 Hypertension (%)

80 (46.0)

23 (43.4)

29 (34.9)

0.742

0.095

0.324

 Diabetes (%)

33 (19.0)

5 (9.4)

11 (13.3)

0.104

0.257

0.502

 Hyperlipidemia (%)

57 (32.8)

18 (34.0)

11 (13.3)

0.871

0.001

0.004

 Cognitive level

   

< 0.001

< 0.001

< 0.001

 CU (%)

102 (58.6)

17 (32.1)

6 (7.2)

   

 MCI (%)

64 (36.8)

20 (37.7)

41 (49.4)

   

 ADD (%)

8 (4.6)

16 (30.2)

36 (43.4)

   
  1. Abbreviations: FMM 18F-flutemetamol, APOE ε4 Apolipoprotein ε4, CU cognitively unimpaired, MCI mild cognitive impairment, ADD Alzheimer’s disease dementia